Senators press HHS on prediction markets tied to drug trials

Two Democratic senators want the federal health department to explain what happens when drug trials become something you can bet on.

Sen. Angela Alsobrooks and Sen. Ron Wyden sent a letter to the Department of Health and Human Services asking about safeguards for prediction market event contracts. The contracts in question are tied to clinical drug trial outcomes and Food and Drug Administration approvals. CNBC obtained the letter first.

What the senators are asking

The core request is simple. Alsobrooks and Wyden want HHS to lay out what protections exist around markets that let traders take positions on whether a drug clears a trial or wins regulatory sign-off.

The question lands squarely on Kalshi. In July 2026, the prediction market platform launched a pilot program that lets users bet on late-stage clinical trial endpoints and FDA decisions.

The pilot covers roughly a dozen FDA-related contracts. Trading volumes for the drug-related contracts have not been reported as of early November 2026.

HHS has not publicly responded to the senators’ inquiry. No enforcement actions tied to these contracts have been reported to date.

Why researchers are uneasy

The senators are not raising this in a vacuum. Researchers from Boston University and other institutions warned in October 2026 that market odds could affect trial integrity and public confidence in outcomes.

Their concerns go beyond the obvious ethics of gambling on a cancer drug. The researchers flagged possible effects on how trial participants behave, including adherence rates. Adherence is clinical shorthand for whether patients actually take the treatment as instructed.

The researchers also pointed to public trust in regulatory processes. They singled out vaccines as an especially sensitive area.

Consumer advocacy group Public Citizen weighed in too. On November 2, 2026, it named betting on clinical trial outcomes its “Outrage of the Month.”

The bigger fight over what can be traded

What makes drug trials different is who holds the information. In an election market, the outcome is decided by millions of voters in public. In a clinical trial, the relevant knowledge sits with a much smaller circle of people working on or participating in the study.

That concentration is exactly why the safeguards question carries weight. Markets work best when information is spread out and hard to monopolize. A late-stage trial is closer to the opposite of that ideal, which helps explain why the senators directed their letter to the health department rather than treating this as a routine trading matter.

What this means

The things to watch are straightforward. First, whether HHS answers the senators publicly and what it says. Second, whether Kalshi expands, holds steady or trims its FDA-related slate. Third, whether trading volume data ever surfaces, since a market nobody uses is far easier to defend than one attracting serious money.

Until then, the drug trial contracts sit in an uncomfortable middle ground: small enough to call an experiment, sensitive enough to draw two senators, a group of academic researchers and a consumer watchdog into the same conversation.